Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453087 | 0.81 | ALDH1A1 (0.67) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL19760706 | 0.80 | IDO1 (0.59) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL29611992 | 0.80 | IDO1 (0.59) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL3262533 | 0.79 | IDO1 (0.51) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL3264403 | 0.78 | IDO1 (0.56) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL3613788 | 0.77 | IDO1 (0.55) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL29671027 | 0.77 | IDO1 (0.55) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL3237839 | 0.75 | KDM4E (0.59) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL3263494 | 0.74 | IDO1 (0.52) | IDO1LMNAPDE4DALDH1A1MAPT | |
| SCHEMBL23743649 | 0.74 | TP53 (0.45) | ALDH1A1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120730-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2010015585-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| EP-2109610-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2, 3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | Nycomed GmbH (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008095835-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2, 3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1953159-A1 | 6-Benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds useful as PDE5 inhibitors | Nycomed GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120730-A1 | 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO [2,3-C] QUINOLINE COMPOUNDS USEFUL AS PDE5 INHIBITORS | PDE5A, PDE3A, PDE2A | IDO1 352/4885LMNA 2585/4885PDE4D 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.